Prostaglandin E2 (PGE2) synthesis pathway is involved in coronary artery stenosis and restenosis

Kakavandi, Naser; Rezaee, Shima; Hosseini‐Fard, Seyed Reza; Khosravi, Mohsen; Shabani, Mohammad; Najafi, Mohammad

doi:10.1016/j.gene.2020.145131

Cited by 8 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is due to the increased collagen deposition owing to TGF-β1 factor activation, which, in contrast, is inhibited by the PGE2/EP4 axis [ 227 ]. It has been noted that 15-PGDH is overexpressed after coronary artery stent implantation in patients affected by vessel stenosis, lowering the inflammation [ 228 ].…”

Section: Prostanoidsmentioning

confidence: 99%

The Link between Prostanoids and Cardiovascular Diseases

Beccacece

Abondio

Bini

et al. 2023

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases are the leading cause of global deaths, and many risk factors contribute to their pathogenesis. In this context, prostanoids, which derive from arachidonic acid, have attracted attention for their involvement in cardiovascular homeostasis and inflammatory processes. Prostanoids are the target of several drugs, but it has been shown that some of them increase the risk of thrombosis. Overall, many studies have shown that prostanoids are tightly associated with cardiovascular diseases and that several polymorphisms in genes involved in their synthesis and function increase the risk of developing these pathologies. In this review, we focus on molecular mechanisms linking prostanoids to cardiovascular diseases and we provide an overview of genetic polymorphisms that increase the risk for cardiovascular disease.

show abstract

Section: Prostanoidsmentioning

confidence: 99%

The Link between Prostanoids and Cardiovascular Diseases

Beccacece

Abondio

Bini

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Prostaglandin E1 (PGE1, also named alprostadil), especially its nanoliposome dosage form, was reported to be able to improve the blood flow by inhibiting platelet aggregation, reducing the inflammatory response, acting on vascular endothelial cells to dilate blood vessels, antithrombolysis, and improving microcirculation, etc. [ 3 , 4 ]. Thus, it has a potential therapeutic effect on the reduction of ISR occurrence after PCI.…”

Section: Introductionmentioning

confidence: 99%

Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis

Decai

Wang

Zhao

et al. 2023

Journal of Interventional Cardiology

View full text Add to dashboard Cite

Background. In-stent restenosis (ISR) is a common complication after percutaneous coronary intervention (PCI) surgery for patients with coronary atherosclerotic heart disease (CHD). Reports indicate alprostadil may reduce ISR, and this study aimed at reviewing and summarizing the effect of nanoliposome alprostadil on ISR by meta-analysis. Methods. Articles were searched from databases, and meta-analysis was performed in Review Manager software. Funnel plots were performed to evaluate the publication bias, and sensitivity analysis was performed to determine the robustness of the overall treatment effects. Results. Initially, 113 articles were identified, and 5 studies of 463 subjects were included for analysis eventually. The primary endpoint, i.e., the occurrence of ISR after PCI, occurred in 11.91% of the alprostadil treatment group (28 from 235 patients) vs. 21.49% of the conventional treatment group (49 from 228 patients) and showed a statistical significance in our pooled data (χ2 = 7.654, P = 0.006 ), while there was no statistically significant difference in all of the separate studies. We observed no statistical methodological heterogeneity among the studies ( P = 0.64 , I2 ≈ 0%). The pooled odds ratio (OR) of the occurrence of ISR was 49% in a fixed-effect model, and the 95% confidence boundary (95% CI) was 29% to 81%. The funnel plot did not show serious publication bias, and sensitivity analysis showed well robustness of the overall treatment effect. Discussion. In conclusion, the early application of nanoliposome alprostadil after PCI could effectively reduce the occurrence of ISR, and the overall effect of alprostadil treatment in reducing ISR after PCI was relatively stable.

show abstract

“…Therefore, inhibiting its synthesis may be one of the ways to reduce inflammation. ( Kakavandi et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Reduning Injection prevents carrageenan-induced inflammation in rats by serum and urine metabolomics analysis

Gao

Wang

Chen

et al. 2022

Chinese Herbal Medicines

View full text Add to dashboard Cite

Prostaglandin E2 (PGE2) synthesis pathway is involved in coronary artery stenosis and restenosis

Cited by 8 publications

References 21 publications

The Link between Prostanoids and Cardiovascular Diseases

The Link between Prostanoids and Cardiovascular Diseases

Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis

Reduning Injection prevents carrageenan-induced inflammation in rats by serum and urine metabolomics analysis

Contact Info

Product

Resources

About